Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17550718 | 0.94 | FFAR1 (0.55) | FFAR1FFAR4KMT2A | |
| SCHEMBL19296740 | 0.93 | GFER (0.50) | FFAR1KMT2A | |
| SCHEMBL17550714 | 0.92 | FFAR1 (0.67) | FFAR1FFAR4KMT2A | |
| SCHEMBL17550701 | 0.90 | FFAR1 (0.63) | FFAR1FFAR4 | |
| SCHEMBL17550669 | 0.89 | FFAR1 (0.54) | FFAR1FFAR4 | |
| SCHEMBL17550648 | 0.88 | FFAR1 (0.54) | FFAR1FFAR4KMT2A | |
| SCHEMBL17550687 | 0.88 | FFAR1 (0.56) | FFAR1FFAR4 | |
| SCHEMBL17550716 | 0.88 | FFAR1 (0.58) | FFAR1FFAR4 | |
| SCHEMBL17550671 | 0.87 | FFAR1 (0.67) | FFAR1FFAR4 | |
| SCHEMBL17550659 | 0.86 | FFAR1 (0.56) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3187488-B1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVE AND USE THEREOF | CJ HEALTHCARE CORP (KR) | 2020-02-19 | — | — | EP | claimed |
| US-20170247320-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVES AND USE THEREOF | CJ HEALTHCARE CORPORATION (KR) | 2017-08-31 | — | — | US | claimed |
| EP-3187488-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVE AND USE THEREOF | CJ Healthcare Corporation (KR) | 2017-07-05 | — | — | EP | claimed |
| EP-3187488-B1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVE AND USE THEREOF | CJ HEALTHCARE CORP (KR) | 2020-02-19 | — | — | EP | disclosed |
| EP-3187488-B1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVE AND USE THEREOF | CJ HEALTHCARE CORP (KR) | 2020-02-19 | — | — | EP | disclosed |
| US-20170247320-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVES AND USE THEREOF | CJ HEALTHCARE CORPORATION (KR) | 2017-08-31 | — | — | US | disclosed |
| US-20170247320-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVES AND USE THEREOF | CJ HEALTHCARE CORPORATION (KR) | 2017-08-31 | — | — | US | disclosed |
| US-20170247320-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVES AND USE THEREOF | CJ HEALTHCARE CORPORATION (KR) | 2017-08-31 | — | — | US | disclosed |
| EP-3187488-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVE AND USE THEREOF | CJ Healthcare Corporation (KR) | 2017-07-05 | — | — | EP | disclosed |
| EP-3187488-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVE AND USE THEREOF | CJ Healthcare Corporation (KR) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016032120-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVE AND USE THEREOF | 씨제이헬스케어 주식회사 | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247320-A1 | NOVEL AMINO-PHENYL-SULFONYL-ACETATE DERIVATIVES AND USE THEREOF | SLC5A2, SLC5A1, IAPP | FFAR1 135/4885FFAR4 102/4885KMT2A 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.